The report discusses the FDA approval of Bristol's Opdivo in combination with Yervoy for previously untreated BRAF wild-type melanoma patients. It highlights the significance of this approval as the first I/O combo approved and its potential impact on stabilizing Yervoy sales. The report also mentions upcoming novel I/O agents and combinations expected to enter the clinic in 2016.
documents/EFTA01087638.pdf
{}